Fimbrion and GSK Identify Novel, Antibiotic-Sparing Development Candidate for Urinary Tract Infections.
ST. LOUIS, Dec. 6, 2018 /PRNewswire/ — Fimbrion Therapeutics, Inc. announced that under its joint research collaboration with GSK, researchers have identified an orally available, small molecule development candidate for the treatment and prevention of urinary tract infections (UTIs). Fimbrion and the Discovery Partnerships with Academia (DPAc) team at GSK began their joint research efforts in July of 2016.